Manogepix
Manogepix (E1210) is an isoxazole-based broad-spectrum antifungal.[1] Manogepix targets GPI-protein biosynthesis.
Clinical data | |
---|---|
Other names | E1210, APX001A |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C12H18N4O2 |
Molar mass | 250.302 g·mol−1 |
3D model (JSmol) | |
| |
|
Manogepix is the active metabolite of the prodrug fosmanogepix.[2]
References
- Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M (October 2011). "In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method". Diagnostic Microbiology and Infectious Disease. 71 (2): 167–170. doi:10.1016/j.diagmicrobio.2011.05.001. PMID 21696907.
- Badali H, Patterson HP, Sanders CJ, Mermella B, Gibas CF, Ibrahim AS, et al. (May 2021). "Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes". Antimicrobial Agents and Chemotherapy. 65 (6). doi:10.1128/AAC.02343-20. PMC 8315997. PMID 33722886.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.